泰诺麦博外籍董事长廖化新年过七旬，曾是美国杜克大学教授

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has been accepted for IPO on the Sci-Tech Innovation Board, marking it as the first company to be accepted under the reactivated fifth set of listing standards [3] Company Overview - Tainuo Maibo, established in 2015, focuses on innovative biopharmaceuticals for blood product replacement therapies targeting global markets [3] - The company has developed several candidate antibody drugs, including the globally first-in-class Staitouta monoclonal antibody injection, which has been approved for market [3] - Other candidates include TNM001 (anti-respiratory syncytial virus monoclonal antibody) in Phase III clinical trials, and TNM009 and TNM005 (anti-nerve growth factor and anti-varicella-zoster virus monoclonal antibodies) which have completed Phase I trials [3] Financial Performance - The company reported revenues of 4.34 million yuan in 2022, 0 yuan in 2023, and 1.51 million yuan in 2024, with a revenue of 16,930 yuan in Q1 2025 following the approval of Staitouta [4] - Net losses were reported at 429 million yuan in 2022, 446 million yuan in 2023, 515 million yuan in 2024, and 177 million yuan in Q1 2025 [4] Key Financial Metrics - As of March 31, 2025, total assets amounted to 1.13 billion yuan, with equity attributable to shareholders at 493 million yuan [5] - The company's debt-to-equity ratio was 56.48% as of Q1 2025, indicating a moderate level of financial leverage [5] - The basic and diluted earnings per share were both -0.48 yuan in Q1 2025, reflecting ongoing losses [5] Management and Ownership - The actual controllers, Huaxin Liao and Zheng Weihong, collectively hold 33.10% of the company's shares [5] - Huaxin Liao, the Chairman and CTO, has a background in biochemistry and extensive experience in molecular immunology [6] - Zheng Weihong, the Vice Chairman and General Manager, has a background in business management and experience in the pharmaceutical industry [7] Compensation - In 2024, Huaxin Liao received a salary of 2.63 million yuan, while Zheng Weihong earned 2.61 million yuan, both lower than the salary of the Chief Medical Officer, Wang Guomei, who earned 3.79 million yuan [8][9]